Table 2 Univariate analyses of factors associated with recurrence-free survival and overall survival
From: ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma
Variables | RFS | OS | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
Gender (male vs. female) | 0.670 (0.351–1.278) | 0.224 | 0.67 (0.348–1.275) | 0.22 |
Age, years (≥50 vs. <50) | 0.630 (0.364–1.089) | 0.098 | 0.776 (0.481–1.203) | 0.363 |
HbsAg (positive vs. negative) | 1.181 (0.425–3.285) | 0.75 | 1.078 (0.385–3.013) | 0.887 |
AFP, ng/ml (>400 vs. ≤400) | 1.713 (0.988–2.970) | 0.055 | 1.519 (0.876–2.634) | 0.136 |
Cirrhosis (yes vs. no) | 1.589 (0.871–2.899) | 0.131 | 1.436 (0.724–1.894) | 0.239 |
Tumor size, cm (≥5 vs. <5) | 3.124 (1.692–5.768) | 0.00 | 2.79 (1.523–5.110) | 0.001 |
AJCC stage (III–IV vs. I–II) | 2.080 (1.108–3.903) | 0.023 | 1.981 (1.056–3.717) | 0.033 |
ASPP2 (high vs. low) | 0.423 (0.221–0.809) | 0.009 | 0.437 (0.229–0.833) | 0.012 |
HMGCR (high vs. low) | 2.095 (1.193–3.679) | 0.01 | 1.979 (1.130–3.466) | 0.017 |
